

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5

C1-C13 Fragment: Problematic Glycal-Epoxyde Solvolysis




FIG. 7

Solution: Eliminate C11 Stereogenic Centrum




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 20




FIG. 21




FIG. 22




FIG. 24




FIG. 25




FIG. 26




FIG. 27




FIG.29




FIG. 30




FIG. 32

24
400 MHz
CDCl₃




FIG. 33




FIG. 34

24 1D-NOE Irradiation at 5.87 ppm
400 MHz
CDCl₃




FIG. 35

24 1D-NOE Irradiation at 1.22 ppm
400 MHz
CDCl₃




FIG. 36

29
400 MHz
CDCl₃




FIG. 37

29 1D-NOE Irradiation at 5.53 ppm
400 MHz
CDCl₃




FIG. 38

29 1D-NOE Irradiation at 4.54 ppm

400 MHz

CDCl₃




FIG. 39

Compound 29 2D NOE
400MHz CDCl₃




FIG. 40




FIG. 41

30
400 MHz
CDCl₃




FIG. 42




FIG. 43




FIG. 45








FIG. 49




FIG. 50




FIG. 51




FIG. 52

36 1D-NOE Irradiation at 5.74 ppm

400 MHz

C₆D₆




FIG. 53




FIG. 54




FIG. 55




FIG. 56

38
400 MHz
CDCl₃




FIG. 57

38 1D-NOE Irradiation at 6.16 ppm
400 MHz
C₆D₆




FIG. 58




FIG. 59




FIG. 60




FIG. 61




FIG. 63




FIG. 65




FIG. 66






FIG. 67


SK-HEP-1 (Peloruside)




HCT-15 (Peloruside)




SK-MEL-5 (Peloruside)



Hep-G2 (Peloruside)



HCT-116 (Peloruside)



SK-MEL-28 (Peloruside)




FIG. 68




FIG. 69




FIG. 70




FIG. 71




FIG. 72




FIG. 73





FIG. 74

PELORUSIDE 10 μ M



PELORUSIDE 5 μ M





FIG. 75

A



B




FIG. 76





FIG. 77

A



B




FIG. 78




FIG. 79






FIG. 80






FIG. 81






FIG. 82






FIG. 83



Reagents and conditions: g) DDQ, $\text{CH}_2\text{Cl}_2/\text{H}_2\text{O}$; h) oxidation to aldehyde; i) LDA, THF, -78°C ; j) oxidation to ketone; k) H^+ ; l) NaBH_4 , $\text{CeCl}_3 \cdot 7\text{H}_2\text{O}$, MeOH; m) mCPBA, NaHCO_3 , $\text{CH}_2\text{Cl}_2/\text{MeOH}$; n) base, R_2X ; o) R_3SiOTf , 2,6-lutidine; p) LiDBB, THF or Li, naphthalene, THF; q) Ru-alkylidene catalyst (cross metathesis); r) conjugate reduction; s) oxidation to aldehyde; t) allylBEt_2 ; u) cat. OsO_4 , NMO; v) $\text{Pb}(\text{OAc})_4$ PMB = p-methoxybenzyl, TES = triethylsilyl, NMO = 4-methylmorpholine-N-oxide, DDQ = 2,3-dichloro-5,6-dicyano-1,4-benzoquinone, LDA = lithium diisopropylamide, mCPBA = m-chloroperbenzoic acid, Bn = benzyl.

FIG. 84




Reagents and conditions: d) ent-10C (prepared from $R^4OCH_2CH=CH_2$, $sBuLi$, THF, $-78^\circ C$, 15 min, then $(-)-lpc_2BOMe$, $-78^\circ C$), then ent-9, $-95^\circ C$, 30% H_2O_2 , NaOH; e) base R_5X ; g) DDQ, CH_2Cl_2/H_2O ; h) oxidation to aldehyde; i) LDA, THF; j) oxidation to ketone; k) H^+ ; l) $NaBH_4$, $CeCl_3 \cdot 7H_2O$, MeOH; m) mCPBA, $NaHCO_3$, $CH_2Cl_2/MeOH$; n) base, R_2X ; o) TESOTf, 2,6-lutidine, CH_2Cl_2 ; p) cat. OsO_4 , NMO, acetone/ H_2O ; q) $Pb(OAc)_4$, pyridine; r) $NaClO_2$, NaH_2PO_4 , 2-Me-2-butene, $tBuOH/H_2O$; s) CH_2N_2 ; t) hydrogenolysis; u) oxidation to aldehyde; v) allyl BEt_2 ; w) cat. OsO_4 , NMO; x) $Pb(OAc)_4$. PMB = p-methoxybenzyl, TES = triethylsilyl, NMO = 4-methylmorpholine-N-oxide, lpc = isopinocampheyl, DDQ = 2,3-dichloro-5,6-dicyano-1,4-benzoquinone, LDA = lithium diisopropylamide, mCPBA = m-chloroperbenzoic acid, Bn = benzyl.

R^2 , R^4 , R^5 can be the same or different and include: alkyl, functionalized alkyl (functionalization may include, inter alia, heteroatoms, halides, aryl, heteroaryl)


FIG. 85

R^2 , R^4 , R^5 can be the same or different and include: alkyl, functionalized alkyl (functionalization may include, inter alia, heteroatoms, halides, aryl, heteroaryl)




Reagents and conditions: g) LDA, THF; h) base R_5X ; i) H^+ ; j) cat. OsO₄, NMO; k) Pb(OAc)₄. TMS = trimethylsilyl, TES = triethylsilyl, NMO = 4-methylmorpholine-N-oxide, LDA = lithium diisopropylamide.

FIG. 86



Reagents and conditions: g) LDA, THF; h) base R_5X ; i) H^+ ; j) cat. OsO_4 , NMO; k) $Pb(OAc)_4$. TMS = trimethylsilyl, TES = triethylsilyl, NMO = 4-methylmorpholine-N-oxide, LDA = lithium diisopropylamide.


FIG. 87



Reagents and conditions: a) Ipc₂Ballyl; b) TESCl; c) cat. OsO₄, NMO; d) Pb(OAc)₄; d) LDA, THF; e) base R₅X; f) H⁺; g) cat. OsO₄, NMO; h) Pb(OAc)₄. TMS = trimethylsilyl, TES = triethylsilyl, NMO = 4-methylmorpholine-N-oxide, LDA = lithium diisopropylamide.

R² can include: alkyl, functionalized alkyl (functionalization may include, inter alia, heteroatoms, halides, aryl, heteroaryl)


FIG. 88



Reagents and conditions: a) $\text{Ipc}_2\text{Ballyl}$; b) TESCl ; c) cat. OsO_4 , NMO ; d) $\text{Pb}(\text{OAc})_4$; e) base R_5X ; f) H^+ ; g) cat. OsO_4 , NMO ; h) $\text{Pb}(\text{OAc})_4$. TMS = trimethylsilyl, TES = triethylsilyl, NMO = 4-methylmorpholine-N-oxide, LDA = lithium diisopropylamide.


R^2 can include: alkyl, functionalized alkyl (functionalization may include, inter alia, heteroatoms, halides, aryl, heteroaryl)

FIG. 89



Reagents and conditions: n) base, R_2X ; o) TESOTf, 2,6-lutidine; p) LiDBB, THf or Li, naphthalene, THF; q) Ru-alkylidene catalyst (cross metathesis); r) conjugate reduction; s) oxidation to aldehyde; t) allylBEt₂; u) cat. OsO₄, NMO; v) Pb(OAc)₄ PMB = p-methoxybenzyl, TES = triethylsilyl, NMO = 4-methylmorpholine-N-oxide, DDQ = 2,3-dichloro-5,6-dicyano-1,4-benzoquinone, LDA = lithium diisopropylamide, mCPBA = m-chloroperoxybenzoic acid, Bn = benzyl.





FIG. 90



Reagents and conditions: i) LDA, THF; j) oxidation to ketone; k) H^+ ; l) $NaBH_4$, $CeCl_3 \cdot 7H_2O$, MeOH; m) mCPBA, $NaHCO_3$, $CH_2Cl_2/MeOH$; n) base, R_2X ; o) TESOTf, 2,6-lutidine, CH_2Cl_2 ; p) cat. OsO_4 , NMO, acetone/ H_2O ; q) $Pb(OAc)_4$, pyridine; r) $NaClO_2$, NaH_2PO_4 , 2-Me-2-butene, $tBuOH/H_2O$; s) CH_2N_2 ; t) hydrogenolysis; u) oxidation to aldehyde; v) allylBEt₂; w) cat. OsO_4 , NMO; x) $Pb(OAc)_4$. PMB = p-methoxybenzyl, TES = triethylsilyl, NMO = 4-methylmorpholine-N-oxide, DDQ = 2,3-dichloro-5,6-dicyano-1,4-benzoquinone, LDA = lithium diisopropylamide, mCPBA = m-chloroperbenzoic acid, Bn = benzyl.

R^2 , R^4 , R^5 can be the same or different and include: alkyl, functionalized alkyl (functionalization may include, inter alia, heteroatoms, halides, aryl, heteroaryl)

FIG. 91



R^2 , R^4 , R^5 can be the same or different and include: alkyl, functionalized alkyl (functionalization may include, inter alia, heteroatoms, halides, aryl, heteroaryl)









FIG. 92



R^2 , R^4 , R^5 can be the same or different and include: alkyl, functionalized alkyl (functionalization may include, inter alia, heteroatoms, halides, aryl, heteroaryl)























FIG. 93



R^2 , R^4 , R^5 can be the same or different and include: alkyl, functionalized alkyl (functionalization may include, inter alia, heteroatoms, halides, aryl, heteroaryl), and where R^8 = aryl, heteroaryl, alkyl, functionalized alkyl, alkenyl, functionalized alkenyl, alkynyl, functionalized alkynyl (functionalization may include, inter alia, heteroatoms, halides, aryl, heteroaryl).

FIG. 94



R^2 , R^3 , R^4 , R^5 can be the same or different and include: alkyl, functionalized alkyl (functionalization may include, inter alia, heteroatoms, halides, aryl, heteroaryl), and where R^8 = aryl, heteroaryl, alkyl, functionalized alkyl, alkenyl, functionalized alkenyl, alkynyl, functionalized alkynyl (functionalization may include, inter alia, heteroatoms, halides, aryl, heteroaryl). The configuration at the carbon bearing the OR^3 substituent can have the *R*- or *S*-configuration.













FIG. 95



R^2, R^3, R^4, R^5 can be the same or different and include: H, alkyl, functionalized alkyl (functionalization may include, inter alia, heteroatoms, halides, aryl, heteroaryl), and where R^8 = aryl, heteroaryl, alkyl, functionalized alkyl, alkenyl, functionalized alkenyl, alkynyl, functionalized alkynyl (functionalization may include, inter alia, heteroatoms, halides, aryl, heteroaryl). The configuration at the carbon bearing the OR^3 substituent can have the *R*- or *S*-configuration









FIG. 96



FIG. 97